We investigated the efficacy of cord blood transplantation (CBT) for adult acute lymphoblastic leukemia (ALL) by reviewing medical records of 256 patients reported to the Japan Cord Blood Bank Network between June 1997 and August 2006. Cumulative incidence of neutrophil engraftment at day 100 was 78%. Infused CD34-positive cell dose (41 Â 10 5 cells/kg) was associated with successful neutrophil engraftment. Cumulative incidence of grade II --IV acute graft-versus-host disease (GVHD) at day 100 was 37%. A 2-year disease-free and overall survival (OS) rates were 36% and 42%, respectively. Multivariate analysis showed that age (51 or older vs younger than 50) (hazard ratio 1.9, 95% confidence interval (CI), 1.3 --2.8, P ¼ 0.001), disease status (non-remission vs remission) (hazard ratio 2.2, 95% CI, 1.5 --3.2, Po0.0001), grade III --IV acute GVHD (hazard ratio 2.0, 95% CI, 1.2 --3.2, P ¼ 0.006) and absence of chronic GVHD (hazard ratio 2.4, 95% CI, 1.1 --5.1, P ¼ 0.02) were negatively associated with OS. CBT is effective for some patients with advanced ALL. It is worth considering for further evaluation.
INTRODUCTION
Adult patients with acute lymphoblastic leukemia (ALL) achieved complete remission with induction chemotherapy in the high rate of 85--90%, although most of them relapse and finally die of disease progression. The indication and timing of allogeneic hematopoietic cell transplantation continue to be debated for adult ALL. 1 --5 Umbilical cord blood is a promising alternative for allogeneic transplantation. It has a great advantage over bone marrow and peripheral blood because of its immediate availability and lack of invasive interventions to donors. The value of cord blood transplantation (CBT) has been intensively evaluated in previous studies. 6 --9 Graft-versus-leukemia effects are associated with graft-versushost disease (GVHD) in allogeneic transplantation for hematological malignancies. 10 Some clinical studies suggested the presence of graft-versus-leukemia effects after CBT in pediatric and adult patients, 7,11 --14 most of them were small sized. At present, limited information is available on the graft-versus-leukemia effects after CBT for adult ALL.
We conducted a retrospective nation-wide study to investigate the usefulness of CBT for adult ALL.
PATIENTS AND METHODS

Data collection
The recipient's clinical data were provided by the Japan Cord Blood Bank Network (JCBBN). All 11 CB banks in Japan are affiliated to JCBBN. The data management committee of JCBBN collects all the recipients' clinical information at day 100, then 1 --5 years after CBT. The numbers of nucleated and CD34-positive cells were provided by the CB banks. The numbers of these cells were measured before cryopreservation. The information on the number of CD3-positive cells in the cord blood was not available.
Between March 1998 and June 2006, 424 adult patients with ALL received CBT and were registered to JCBBN. All recipients received a single cord blood unit. We excluded 77 patients with a history of any types of allogeneic transplantation before CBT. We also excluded adult T-cell leukemia/lymphoma because of its different disease entity. Finally, a total of 256 patients met the criteria. Some of them were reported previously in other studies. 15 --18 Approval for this study was obtained from the JCBBN institutional review board. CB units were provided with written informed consent in accordance with the Declaration of Helsinki Principles, which approved by the institutional review board of each participating institution.
Definitions and endpoints
Day of neutrophil engraftment was defined as the first of 3 consecutive days on which absolute neutrophil count was 4500 cells/ml. Graft failure was diagnosed when neutrophil recovery was not achieved within 60 days of transplantation. GVHD was graded according to the criteria published previously. 19 Relapse was defined as presence of ALL cells based on morphological evaluation of the bone marrow or other sites. Patients who had never achieved complete remission after CBT were considered to have progression on day 0. Treatment-related mortality (TRM) was defined as deaths without progression of ALL. Reduced-intensity regimens were defined as reported previously. 20, 21 Statistical analysis
The available data were as of October 2006. The data sets were fixed in March 2008, and we analyzed them between April 2008 and October 2010. The probabilities of overall survival (OS) and disease-free survival (DFS) were estimated by the Kaplan --Meier method. Cumulative incidence curves were used in a competing-risk setting to calculate the probability of engraftment, acute and chronic GVHD, relapse and TRM. For neutrophil and platelet engraftment, death before neutrophil and platelet recovery within 60 days of transplant was the competing event; for GVHD, disease relapse and engraftment failure without GVHD, and deaths within 60 days of transplant without GVHD were the competing events; for relapse, death without relapse was the competing event; and for TRM, death with disease relapse was the competing event. 22 Associations between potential prognostic factors and outcomes were evaluated using the Cox's proportional hazard regression models. The following variables were considered as covariates: age, body weight, human leukocyte antigen mismatch, blood-type mismatch, sex mismatch, infused nucleated cell dose and CD34-positive cell dose, status of underlying disease at transplantation, chromosomal abnormality, preparative regimens and GVHD prophylaxis. Occurrence of acute GVHD was added to the models as a time-dependent covariate. SAS version 9.1.3 (SAS Institute Inc., Cary, NC, USA) was used for all statistical analyses.
RESULTS
Patients' characteristics
Patients' characteristics are shown in Table 1 . The median followup of the surviving patients was 20.5 months (range, 1.1 --86.4). Ph-positive ALL comprised 39% of the population analyzed. No patients received tyrosine kinase inhibitors for maintenance following CBT.
Engraftment
Of the 256 patients, 190 (74%) achieved primary neutrophil engraftment at a median of day 24 (range 11 --51) and 44 (17%) died without engraftment. Median time to platelet recovery (420 000/ml) was day 46 (range 20 --179).
Of the remaining 22, who survived without neutrophil engraftment, 14 received second transplantation as stem-cell rescue. The other eight survived without neutrophil engraftment. Their disease status at last follow-up was remission after autologous recovery (n ¼ 4) and non-remission (n ¼ 4). The diagnosis of primary and secondary graft failure was established in 22 and 10 patients, respectively.
Cumulative incidence of neutrophil engraftment at day 100 was 78% (95% confidence interval (CI), 73 --84%). The cumulative incidence of platelet recovery to 20 000/ml at day 100 was 64% (95% CI, 58 --70%). The prognostic factors for neutrophil and platelet engraftment were shown in Table 2 .
GVHD
The cumulative incidence of grade II --IV acute GVHD at day 100 is 37% (95% CI, 30 --43%). No prognostic factors were identified in multivariate analysis for grade II --IV acute GVHD, whereas the number of infused nucleated cells, conditioning regimens, GVHD prophylaxis and the number of human leukocyte antigen disparities were examined.
Chronic GVHD was diagnosed in 41 of the 180 evaluable patients, who survived longer than 100 days. The cumulative incidence of chronic GVHD at 2 years after CBT was 24% (95% CI, 21 --28%). Of the 41 patients, 27 and 14 developed limited and extensive diseases, respectively. The presence of grade III --IV acute GVHD and the number of CD34-positive cells were the prognostic factors of chronic GVHD (Table 2) .
Complications other than GVHD Infections were documented in 129 patients (50%). They included bacterial (n ¼ 85), fungal (n ¼ 16) and viral infection (n ¼ 52). Cytomegalovirus antigenemia was detected in 111 patients (43%).
Non-infectious complications other than GVHD occurred in 41 patients (16%); interstitial pneumonitis (n ¼ 13), acute respiratory distress syndrome (n ¼ 12), hepatic veno-occlusive disease (n ¼ 13), thrombotic microangiopathy (n ¼ 20) and hemorrhage from any sites (n ¼ 18). A total of 89 patients (35%) died of TRM at a median day of 46 days (range, 4 --466). The cumulative incidence of TRM at 2 years after CBT was 32% (95% CI, 26 --38%). Causes of death included infection (n ¼ 36), acute GVHD (n ¼ 11), veno-occlusive disease (n ¼ 10), graft failure (n ¼ 6), idiopathic pneumonia syndrome (n ¼ 7), thrombotic microangiopathy (n ¼ 6), multiple organ failure (n ¼ 6), hemorrhage (n ¼ 5) and infarction (n ¼ 2).
Response to CBT Out of 78 patients, 24 who were transplanted in non-remission achieved durable remission lasting 60 days or longer and 19 survived without relapse longer than 1 year.
Relapse
The cumulative incidence of relapse at 2 years was 43% (95% CI, 38 --47%). Disease status and the number of nucleated cells at cryopreservation were the prognostic factors in multivariate analysis (Table 2) .
DFS and OS
Probabilities of 2-year DFS and OS were 36% (95% CI, 33 --39%) and 42% (95% CI, 39 --45%), respectively. In the 177 patients transplanted in remission, DFS and OS were 45% (95% CI, 41 --49%) and 51% (95% CI, 46 --55%), respectively. In those who were transplanted in non-remission, DFS and OS were 16% (95% CI, 12 --21%) and 23% (95% CI, 17 --28%), respectively ( Figure 1 ). In patients with Ph-positive ALL, probabilities of 2-year DFS and OS were 32% (95% CI, 27 --37%) and 43% (95% CI, 37 --48%), respectively.
Multivariate analysis showed that age (51 or older vs younger than 50), disease status (non-remission vs remission), absence of chronic GVHD and grade III --IV acute GVHD were negatively associated with OS (Table 2) . Disease status and grade III --IV acute GVHD were negatively associated with DFS (Table 2) .
OS was shown according to the presence of acute and chronic GVHD among the 180 patients who survived longer than 100 days (Figure 2) . Patients with grade III --IV acute GVHD had poor prognosis compared with those with grade 0 --I and grade II acute GVHD. The patients who developed chronic GVHD was expected higher survival rates than patients of absence chronic GVHD.
DISCUSSION
The present study showed that 24 of the 78 patients transplanted in primary refractory or relapse achieved durable remission. Considering that combination chemotherapy is usually ineffective at prolong survival in adult patients with advanced or Ph-positive ALL, 23, 24 the long-term DFS after CBT suggests that durable allogeneic immune reactions continue to suppress leukemic progression after CBT. These findings support the hypothesis that graft-versus-leukemia effects exist after CBT for adult ALL.
Cumulative incidence of grade II --IV acute GVHD at day 100 is 37%. These findings were comparable with previous studies on CBT (26 --60%) . 6, 25 However, it should be noted that grade III --IV acute GVHD negatively impacted OS, and that there was no significant differences between patients with grade 0 --I acute GVHD and those with grade II acute GVHD. These findings suggest that control of acute GVHD is important in CBT for ALL.
Previous studies showed that presence of chronic GVHD protected relapse following CBT for adult ALL, 9,14 whereas it had no significant impact on OS and DFS. Chronic GVHD was not identified as a prognostic factor for relapse in either analysis for patients transplanted in remission or that for patients with active disease at time of transplant. These findings were in contrast to our study, in which chronic GVHD was associated with better OS. Notably, chronic GVHD was limited-type in two-thirds of the patients in this study, and extensive-type chronic GVHD was dominant in the previous study.
14 The mild features of chronic GVHD among Japanese patients following CBT probably lead to the favorable impact of chronic GVHD on OS. 15 This study provided detailed information on the prognostic factors of CBT for adult ALL patients. The number of infused CD34-positive cells was associated with engraftment. Concerning OS, patients' age, disease status and development of acute and chronic GVHD were significant risk factors. These findings were comparable to previous reports. 7, 25 Clinical decision making as to when to proceed with CBT in patients with ALL is difficult. Disease status is an important prognostic factor in CBT. As some patients with second or further remission and those with induction failure achieved durable remission after CBT, they are candidates for CBT. However, it is controversial whether CBT should be offered to patients in first remission, as CBT is associated with a high mortality.
TRM is a significant concern in CBT. The present study demonstrated that most TRM occurred early after transplantation, as consistent with the previous studies. 9, 17 Early infection before engraftment is a significant complication in CBT, and the long duration of neutropenia might have a major role in its pathogenesis. As the higher number of infused CD34-positive cells was a significant predictive factor for engraftment in this study, selection of cord blood units with a higher number of CD34-positive cells may be reasonably expected to reduce the risk of graft failure. Use of double CBT was another option. Some researchers reported that infused cell doses and increased alloreactivity induced by interaction between the two CB units may be responsible for reduced risk of relapse. 11 Our study indicates that CBT is worth considering options for adult ALL further intense evaluation. As a result of the advances in supportive care with better management of infectious complications, and the accumulation of knowledge of better cord blood selection, the outcomes of CBT were significantly improved over time. 8 In addition, reduced-intensity regimens are used widely for CBT, and some small-sized clinical trials suggested that reducedintensity transplantation potentially results in modest TRM, limited risk of relapse and promising survival in adult patients with ALL. 
